High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

被引：79

作者：

Brannagan, TH

Pradhan, A

Heiman-Patterson, T

Winkelman, AC

Styler, MJ

Topolsky, DL

Crilley, PA

Schwartzman, RJ

Brodsky, I

Gladstone, DE

机构：

[1] MCPHU, Dept Neurol, Philadelphia, PA USA

[2] MCPHU, Dept Internal Med, Div Hematol Oncol, Philadelphia, PA USA

来源：

NEUROLOGY | 2002年 / 58卷 / 12期

关键词：

D O I：

10.1212/WNL.58.12.1856

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

引用

收藏

页码：1856 / 1858

页数：3

相关论文

共 10 条

[1] Sural nerve T-cell receptor Vβ gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy [J].

Bosboom, WMJ ;

van den Berg, LH ;

Mollee, I ;

Sasker, LD ;

Jansen, J ;

Wokke, JHJ ;

Logtenberg, T .

NEUROLOGY, 2001, 56 (01) :74-81

[2] Chronic inflammatory demyelinating polyneuropathy [J].

Briani, C ;

Brannagan, TH ;

Trojaborg, W ;

Latov, N .

NEUROMUSCULAR DISORDERS, 1996, 6 (05) :311-325

[3] Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia [J].

Brodsky, RA ;

Sensenbrenner, LL ;

Smith, BD ;

Dorr, D ;

Seaman, PJ ;

Lee, SM ;

Karp, JE ;

Brodsky, I ;

Jones, RJ .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :477-483

[4] Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].

Brodsky, RA ;

Petri, M ;

Smith, BD ;

Seifter, EJ ;

Spivak, JL ;

Styler, M ;

Dang, CV ;

Brodsky, I ;

Jones, RJ .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035

[5] Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy [J].

Good, JL ;

Chehrenama, M ;

Mayer, RF ;

Koski, CL .

NEUROLOGY, 1998, 51 (06) :1735-1738

[6] Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy [J].

Gorson, KC ;

Allam, G ;

Ropper, AH .

NEUROLOGY, 1997, 48 (02) :321-328

[7]

KISSEL JT, 2001, DIAGNOSIS MANAGEMENT, P173

[8] Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy [J].

Nagamatsu, M ;

Terao, S ;

Misu, K ;

Li, M ;

Hattori, N ;

Ichimura, M ;

Sakai, M ;

Yamamoto, H ;

Watanabe, H ;

Riku, S ;

Ikeda, E ;

Hata, J ;

Oda, M ;

Satake, M ;

Nakamura, N ;

Matsuya, S ;

Hashizume, Y ;

Sobue, G .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (06) :727-733

[9] Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease [J].

Nousari, HC ;

Brodsky, RA ;

Jones, RJ ;

Grever, MR ;

Anhalt, GJ .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (05) :750-754

[10] P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy [J].

Yan, WX ;

Archelos, JJ ;

Hartung, HP ;

Pollard, JD .

ANNALS OF NEUROLOGY, 2001, 50 (03) :286-292